Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy of 5% trisodium citrate versus low-dose heparin as catheter-locking solutions for central venous hemodialysis catheters
TCTR20231106002Phase 4Unknown
- Sponsor
- Thammasat University Research Administration
- Start
- Jun 2023
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 4 trial of trisodium citrate, heparin in end-stage kidney disease (ESKD), sponsored by Thammasat University Research Administration. Status: unknown.
02
Drugs
trisodium citrateheparin
03
Conditions
end-stage kidney disease (ESKD)
Beyond the preview
Go deeper on TCTR20231106002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20231106002.